Profile

Pattern Pharma is developing innovative therapeutics that harness the innate immune system to combat cancer and infectious disease. Pattern’s lead drug candidate, PP-100, solves a long-standing challenge of safely and effectively agonizing TLR4. Pattern plans to submit an IND with the FDA in 2023 to commence a Phase 1b/2a study in solid tumor cancer patients. Intellectual property includes a composition of matter patent (July 2019), a method of treatment patent (Nov 2020) & proprietary manufacturing.


Event details

Date: June 5 - 8, 2023

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

33 in total